News

John LaMattina, FORBES CONTRIBUTOR In the summer of 1993, Dr. Paul Changelian, a scientist in Pfizer’s immune suppression group, was looking for a new way to prevent organ transplant rejection. Paul, always on the lookout for new ideas, particularly ones related to suppressing an overactive immune systems (a hallmark of diseases like psoriasis and rheumatoid…

Innovations: John O’Shea and Arthritis Drug BY ADAM THOMAS You may have seen ads on television for Xeljanz (tofacitinib), a drug used to treat rheumatoid arthritis. Don’t ask me where the name came from. But I can tell you that the drug itself was the brainchild of NIH physician and immunologist John O’Shea. O’Shea, who…

Confluence Attending Society for Laboratory Automation & Screening (SLAS) 2017 – February 4-8, 2017 Washington DC. Please visit us at Booth #1350.

CHICAGO, IL – September 25, 2015 — SAMDI Tech and Confluence Discovery Technologies are expanding their service offering by entering into a partnership agreement, allowing SAMDI Tech and Confluence Discovery Technologies to mutually promote their respective services. The two companies aim to offer a range of services from drug discovery to preclinical development, combining their…

Reprinted from STLToday, Monday, April 28, 2014 11:47 AM   Summer STARS program at University of Missouri–St. Louis sees record enrollment   BY UMSL | Posted: Monday, April 28, 2014 11:47 AM This summer’s six-week session of Students and Teachers as Research Scientists (STARS) at the University of Missouri–St. Louis will be one for the…

Confluence Discovery Technologies will be attending the 2013 AAPS Annual Meeting and Exposition November 10-14, 2013 in San Antonio, TX.  If attending, please stop by our booth #3248 to speak with our scientists.

Confluence Discovery Technologies, Inc. will be at the 2013 BIO International Convention April 22-25, 2013 in Chicago, IL. We will be at the Missouri Pavilion (location Ex-2005a). http://convention.bio.org